A comprehensive blood-based screening service designed to detect multiple cancer types simultaneously through gene methylation analysis. This service utilizes advanced NGS technology and is available as a clinical testing service.
Manufactured by
China
BioChain (Beijing) Science & Technology Inc. is a pioneer in cancer early diagnosis and screening in China. The company specializes in developing NGS and PCR-based cancer gene methylation detection products, focusing on early cancer diagnosis reagent kits and large-scale laboratory screening platforms.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Yashraj Biotechnology GmbH
Germany · 1 relevant product
PreceDo Pharmaceuticals Co.Ltd.
China · 2 relevant products
Eone-Diagnomics Genome Center
South Korea · 5 relevant products
55 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →17 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 94 closest product alternatives
Yashraj Biotechnology GmbH · Germany
Comprehensive service for discovering and identifying new cancer biomarkers in human serum and plasma samples to advance precision medicine and diagnostics.
PreceDo Pharmaceuticals Co.Ltd. · China
A high-throughput drug sensitivity testing platform utilizing renewable primary cancer cells to predict treatment response. This service enables personalized treatment selection through comprehensive chemotherapy and targeted drug profiling.
Eone-Diagnomics Genome Center · South Korea
A noninvasive liquid biopsy service based on next-generation sequencing (NGS) technology that analyzes fetal DNA from maternal blood starting from week 10 of pregnancy in singletons and week 12 in twins. The service provides fetal sex identification and comprehensive chromosomal abnormality screening.
91 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products